Cellceutix has acquired exclusive rights to several compounds to address unmet medical needs. We are currently focused on developing our lead clinical and pre-clinical compounds for indications in oncology, dermatology and antibiotics. Kevetrin™, is currently undergoing clinical trials at Harvard Cancer Centers’ Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center, among the world’s leading institutions for cancer treatment and research.
Cellceutix to Start Brilacidin Phase 3 Program in ABSSSI
